Kiora Pharmaceuticals (KPRX) Competitors

Telomir Pharmaceuticals (NASDAQ:TELO) and Kiora Pharmaceuticals (NASDAQ:KPRX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations.

Do analysts rate TELO or KPRX?

Telomir Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 1,227.43%. Kiora Pharmaceuticals has a consensus price target of $10.00, indicating a potential upside of 233.33%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Telomir Pharmaceuticals is more favorable than Kiora Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telomir Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
Kiora Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor TELO or KPRX?

In the previous week, Kiora Pharmaceuticals had 1 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Kiora Pharmaceuticals' score of 0.93 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Telomir Pharmaceuticals	Very Positive
Kiora Pharmaceuticals	Positive

Is TELO or KPRX more profitable?

Kiora Pharmaceuticals' return on equity of -42.82% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telomir Pharmaceuticals	N/A	-2,009.40%	-1,009.72%
Kiora Pharmaceuticals	N/A	-42.82%	-32.18%

Which has better valuation & earnings, TELO or KPRX?

Kiora Pharmaceuticals has higher revenue and earnings than Telomir Pharmaceuticals. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telomir Pharmaceuticals	N/A	N/A	-$16.53M	-$0.42	-2.69
Kiora Pharmaceuticals	$16.02M	0.57	$3.60M	-$2.90	-1.03

Which has more volatility and risk, TELO or KPRX?

Telomir Pharmaceuticals has a beta of -0.9, meaning that its stock price is 190% less volatile than the S&P 500. Comparatively, Kiora Pharmaceuticals has a beta of -0.66, meaning that its stock price is 166% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in TELO or KPRX?

77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Kiora Pharmaceuticals beats Telomir Pharmaceuticals on 9 of the 14 factors compared between the two stocks.